The proportion of BRCA1- and BRCA2-deficient breast cancers in WSI available for genomic and transcriptomic analysis was 14% and 16%, respectively, whereas the proportion of BRCA1- and BRCA2-deficient breast cancers in TCGA available for genomic and transcriptomic analysis was 6.3% and 5.9%, respectively. This evidence concerns the gene BRCA2 and breast carcinoma.